Progress in preconditioning regimen of autologous hematopoietic stem cell transplantation for treatment of multiple myeloma / 白血病·淋巴瘤

ABSTRACT

High-dose melphalan (Mel) is considered as a current standard preparative regimen in autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Irradiation in total body (TBI) combined with Mel is not superior to Mel alone, and the adverse reactions are increased at the same time. The efficacy of 200 mg/m2 Mel is much better than that of 100-140 mg/m2 Mel in young patients. Several regimens including MelBU, TBC, BCV, MET, MTC, MelBCNU, VMel, MTC as well as bendamustine have similar treatment outcomes compared with 200 mg/m2 Mel. Other strategies need to be evaluated in different trials.